Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Moisture-associated Skindamage in Nursinghomes

Wound of Skin Clinical Trial

— ISR-CASP-MASD  

Official title:

The Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Partial-thickness Wounds Caused by Moisture-associated Skin Damage Compared to Usual Wound Care Treatment in Nursing Homes: a Multi-centre RCT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06178289
• Other study ID #: ONZ-2022-0527
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2024
• Est. completion date: February 2025

Study information

• Verified date: May 2024
• Source: University Ghent
• Contact: Hannelore Hofman
• Phone: +32494489497
• Email: hannelore.hofman[@]ugent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Objectives: The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the treatment of partial-thickness wounds caused by moisture (MASD) compared to usual wound care treatment in Belgian nursing homes.

Methodology:

RESEARCH DESIGN: A randomized controlled multicentre clinical trial.

DATA COLLECTION:

Randomization/Blinding and Participant Numbering: The patients will be allocated 1:1 by block randomization, using the REDCap Randomization Module, to either Cavilon™ Advanced Skin Protectant or local nursing home partial-thickness wound (MASD) treatment protocol, yielding one study group. Due to the obvious differences between the comparative nursing home wound care treatment products and the study device, the study nurses cannot be blinded. A blinded assessor will centrally assess the time to healing and other healing outcomes based on the photographs of the study area.

Study area: Defined as all partial-thickness, skin damaged areas on the body - due to exposure to (a) incontinence body fluids, (b) wound exudate, (c) stomal- or fistula effluent or digestive secretions.

Study duration: 21 days or until complete healing of the moisture associated skin damage (complete epithelialization).

Skin (MASD) assessment: Daily skin assessment of the study area is to be conducted by the study nurses. Relevant wound and patient information will be recorded (incontinence status, presence of a urinary catheter or faecal management system, number of absorbent pad or diaper changes, number of cleansing procedures, type of stoma, number of applications regarding Cavilon Advanced Skin Protectant or usual nursing home wound treatment protocol). Digital planimetry software (PictZar® version 7.6.1 ss) will be the main mode of assessing wound healing. Therefore, daily photographs will be taken with each daily skin assessment after removal of all visual product to ensure blinded skin assessment by the central reviewer.

Pain assessment: The Wong-Baker FACES® Pain Rating Scale will be used to assess pain daily. Treatment-related pain (pain experienced during treatment (cleansing and product application)) and wound related pain (pain perception specifically caused by the MASD lesion) will be assessed.

Nursing time assessment: Time per cleansing and time per treatment application.

Description:

Problem statement:

Partial-thickness wounds (erosion/denudation of the epithelial and dermal layers of the skin) can occur due to prolonged exposure of moisture and irritants (Gray et al., 2017). Various sources of moisture can cause these superficial wounds called moisture-associated skin damage (MASD) which include wound exudate, bodily fluids from incontinence and effluent from stomas and fistulas (Woo et al., 2017). MASD can present as inflammation with or without erosion and even secondary infection (Gray et al., 2011). Partial-thickness denudation can be extremely painful and detrimental to the patient. Traditionally a wide array of treatment options is used in clinical practice, yet there is a lack of robust studies comparing newer technologies with current practices (Woo et al., 2017). 3M™ Cavilon™ Advanced Skin Protectant, launched in 2017, is a newer cyanoacrylate-based medical device indicated for treatment of partial-thickness skin loss and is the only cyanoacrylate-based barrier product available on the Belgian market.

Objectives: The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the treatment of partial-thickness wounds caused by moisture (MASD) compared to usual wound care treatment in Belgian nursing homes.

Methodology:

RESEARCH DESIGN: A randomized controlled multicentre clinical trial.

DATA COLLECTION:

Procedure: Demographics and Participant Characteristics: Resident demographics will be recorded in REDCap eCRFs on study schedule Day 01: gender, age, height, weight, co-morbidities.

Randomization/Blinding and Participant Numbering: The patients will be allocated 1:1 by block randomization, using the REDCap Randomization Module, to either Cavilon™ Advanced Skin Protectant or local nursing home partial-thickness wound (MASD) treatment protocol, yielding one study group. Due to the obvious differences between the comparative nursing home wound care treatment products and the study device, the study nurses cannot be blinded. A blinded assessor will assess the time to healing and other healing outcomes centrally based on the photographs of the study area.

Study area: Defined as all partial-thickness, skin damaged areas on the body - due to exposure to (a) incontinence body fluids, (b) wound exudate, (c) stomal- or fistula effluent or digestive secretions.

Study duration: 21 days or until complete healing of the moisture associated skin damage (complete epithelialization).

Hypothesis: 3M™ Cavilon™ Advanced Skin Protectant is more effective in the treatment of partial-thickness wounds caused by moisture (moisture-associated skin damage) compared to usual wound care treatment in nursing homes.

Skin (MASD) assessment: Daily skin assessment of the study area is to be conducted by the study nurses. Relevant wound and patient information will be recorded. This information includes incontinence status, presence of a urinary catheter or faecal management system, number of absorbent pad or diaper changes, number of cleansing procedures, type of stoma, number of applications regarding Cavilon Advanced Skin Protectant or usual nursing home wound treatment protocol. Daily photographs will be taken with each daily skin assessment after removal of all visual product to ensure blinded skin assessment by the central reviewer. Digital planimetry software (PictZar® version 7.6.1 ss) will be the main mode of assessing wound healing. The central reader will perform a blinded skin assessment based on the provided photographic documentation of the study area.

Pain assessment: The Wong-Baker FACES® Pain Rating Scale will be used to assess pain daily. Treatment-related pain (pain experienced during treatment (cleansing and product application)) and wound related pain (pain perception specifically caused by the MASD lesion) will be assessed.

Nursing time assessment: Time per cleansing and time per treatment application will be done on days 4 and 7 using a stopwatch.

DATA ANALYSIS:

All quantitative data will be summarized with descriptive statistics.

Inferential analysis: Cox proportional hazards will be used to calculate the primary efficacy variable. Linear mixed logistic regressions and linear mixed models will be used to calculate the secondary objectives.

Exploratory analysis: Cox proportional hazards will be used to calculate the primary efficacy variable. Linear mixed logistic regressions and linear mixed models will be used to calculate the secondary objectives.

Health economic evaluation: A cost-effectiveness analysis will be performed with an institutional perspective in a Belgian context. Total cost will be calculated by the sum of the total product cost and the total cost of nursing time. Costs will be averaged within each group and compared using a two-signed t-test at an alpha level of 5%. A cost-effectiveness analysis will be performed by calculating the ICER. The ICER will be expressed in euros per wound healed per patient.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: February 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The resident or their legally authorized representative signed informed consent.

• The resident is expected to be in the study for the full duration of the trial.

• The resident has partial thickness wounds caused by moisture (MASD) i.e.,

• The patient has IAD category 2A or

• Peri-wound MASD or

• Peri-stomal MASD.

Exclusion Criteria:

• Residents with a known hypersensitivity or allergy to acrylate or cyanoacrylate.

• The resident requires topical treatment due to a fungal, bacterial or viral infection in the study area.

• Intertriginous dermatitis (most often a fungal infection is present).

• Peri-fistula MASD (would usually require hospitalization).

• The resident has any other local dermatological disease or skin condition interfering with this study.

• Residents participating in another study with a known or implied effect on skin barrier function.

• Residents who are receiving end-of-life care.

Related Conditions & MeSH terms

• Dermatitis
• Wound of Skin

Intervention

Device:
• 3M Cavilon Advanced Skin Protectant
3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
• Standard nursing home treatment protocol
Comparator: Standard nursing home treatment protocol

Locations

Country	Name	City	State
Belgium	WZC Elisabeth aan Zee	Oostende

Sponsors (2)

Lead Sponsor	Collaborator
University Ghent	3M

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to complete epithelialization	Number of days from commencement of application of study device or comparator to the study area to complete resolution of partial-thickness wound	Day 01 - Day 21
Secondary	Proportion of participants with complete epithelialization	The proportion of patients with partial-thickness wounds completely healed at days 7, 14 and 21	Day 07, Day 14, Day 21
Secondary	Mean change in treatment related pain	The mean change in patients' perception of treatment-related pain using the Wong-Baker FACES Pain Rating Scale from baseline to day 21.	Day 01 - Day 21
Secondary	Mean change in wound pain	The mean change in patients' perception of wound pain using the Wong-Baker FACES Pain Rating Scale before treatment, 30 minutes after the first treatment, 24 hours after the first treatment, on day 4, and on day 7.	Day 01, Day 02, Day 04, Day 07
Secondary	Change in maceration surface area	The percent of change in maceration (area) at days 7, 14, and 21.	Day 07, Day 14, Day 21
Secondary	Total treatment cost	To investigate the total cost of treating partial-thickness wounds including number of applications, product costs and nursing time assessments to measure time per cleansing and time per treatment application on day 4 and 7 (by researcher).	Day 04, Day 07